Novavax mentioned on Thursday its two-dose vaccine was 80% efficient towards COVID-19 in a late-stage trial testing the shot in teenagers aged 12 to 17 years.
The trial concerned 2,247 adolescents and occurred between Could and September final 12 months when the Delta variant was the dominant pressure in america. The vaccine was 82% efficient towards the variant.
The US biotech mentioned it expects to submit purposes to international regulators for the shot’s use in adolescents through the first quarter.
Novavax late final month filed for authorization of the shot in U.S. adults, a much-awaited step following months of struggles with improvement and manufacturing issues.
The vaccine has obtained authorizations from the European Union and the World Well being Group and has been cleared to be used in adults in international locations together with the UK and New Zealand.
Within the firm’s trial in adults, which enrolled about 30,000 members in america and Mexico, the vaccine had an efficacy of 90.4%.
Novavax mentioned it didn’t see any incidents of myocarditis within the adolescent information however mentioned it was preserving a detailed eye on the inflammatory coronary heart situation and some other hostile occasions because it deploys its vaccine within the broader inhabitants.
“In order we deploy the vaccine within the broader inhabitants, we’re preserving a really shut eye on this and the opposite hostile occasions related to vaccination. We will ensure we inform the general public and regulators about how our most efficiency from security perspective,” mentioned Filip Dubovsky, chief medical officer.